Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation

Takamatsu Hiroyuki, Araki Raita, Nishimura Ryosei, Yachie Akihiro, Espinoza J. Luis, Okumura Hirokazu, Yoshida Takashi, Kuzushima Kiyotaka, Nakao Shinji

Journal of Clinical Virology
Volume 80
Page range 82-86
Year 2016-06-01
URL http://hdl.handle.net/2297/45519
Epstein–Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation

Hiroyuki Takamatsu¹, Raita Araki², Ryosei Nishimura², Akihiro Yachie², J. Luis Espinoza¹, Hirokazu Okumura³, Takashi Yoshida³, Kiyotaka Kuzushima⁴ and Shinji Nakao¹

¹Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
²Department of Pediatrics, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
³Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan
⁴Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan

Corresponding Author: Hiroyuki Takamatsu, MD, PhD
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
Telephone: +81-76-265-2276
Fax: +81-76-234-4252
Email: takamaz@staff.kanazawa-u.ac.jp

Keywords: Epstein-Barr virus, post-transplant lymphoproliferative disease, rituximab, cidofovir, donor lymphocyte infusion

Word count of abstract: 66
Word count of text: 1582
ABSTRACT

Leukemic Epstein–Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load.

1. Why this case is important

EBV-PTLD following allogeneic hematopoietic stem-cell transplantation presents with serious complications. Among them, leukemic lymphoma is extremely rare but could be fatal, and appropriate treatments are currently unknown. Here we report a successful case of treating EBV-associated leukemic lymphoma with rituximab, cidofovir, and DLI in addition to our previous treatment experience of EBV-associated leukemic lymphoma.

2. Case description

Case 1

A 34-year-old woman was diagnosed with severe aplastic anemia (AA) in 1997. Although she received anti-thymocyte globulin (ATG) along with cyclosporin (CsA) and androgen therapy, her AA progressed. In 2012, she received an allogeneic bone marrow transplantation (BMT) from an unrelated donor who was an HLA match except
one HLA-DRB1 allele (recipient HLA, A 24:02/33:03, B 48:01/51:01, Cw 08:03/14:02,
DRB1*09:01/09:01; donor HLA, A 24:02/33:03, B 48:01/51:01 Cw 08:03/14:02
DRB1*09:01/11:01). The conditioning regimen included total-body irradiation (TBI) (2 Gy on day −1), total-lymphoid irradiation (TLI) (3 Gy on day 0), fludarabine (Flu) (30 mg/m²/day on days −5, −4, −3, and −2), cyclophosphamide (CY) (25 mg/kg/day on days −5, −4, −3, and −2), and ATG (Thymoglobulin, 2.5 mg/kg/day on day −5 and −4). Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus (from day −1) and short-term methotrexate (5 mg/m²/day on days 1, 3, and 6). Both donor and recipient were EBV positive before transplantation. The neutrophil count surpassed 500/µl on day 16 after BMT. She developed a high fever, systemic lymphadenopathy, and hepatosplenomegaly on day 38. The WBC count was 3790/µl with 4% leukemic lymphocytes that were positive for EBV-encoded mRNA, as demonstrated by in situ hybridization and donor type cells by chimerism analysis. Flow cytometry (FCM) of peripheral-blood lymphocytes revealed that virtually all B cells expressed CD19⁺, CD20⁺ and Igκ. The EBV-DNA copy number was 23970/ml of blood and 48000/ml of serum. EBV clonality was confirmed by Southern blotting using the EBV terminal-repeat probe and an IgH PCR assay. sIL-2R level was 1523 U/ml and anti-EBV antibody titer was as follows: EBV anti-VCA IgG, 80×; EBV anti-VCA IgM, <10×; EBV anti EA-DR IgG, <10×; EBV-anti EBNA, 10×. Although a bone-marrow aspiration (BMA) was not performed because of her severe condition on day 38, BMA study showed 11% leukemic lymphocytes in bone marrow on day 40 after rituximab treatment. She was therefore diagnosed as having EBV-associated leukemic lymphoma. Following discontinuation of tacrolimus on day 38, we treated the patient with rituximab (375 mg/m²/day on days 38, 42, 47, 54, and 86), cidofovir (5 mg/kg/day on
days 41 and 48), and DLI (1 × 10⁶ CD3⁺ cells/kg on day 46), after the approval by the Institutional Review Board of Kanazawa University. No renal impairment was observed after the cidofovir treatment. The blood CD19⁺ atypical lymphocyte count decreased to 0/µl on day 48, and her systemic lymphadenopathy resolved. However, the CD8⁺ HLA-DR⁺ lymphocyte count increased to 10230/µl on day 53. Detection of EBV-specific cytotoxic T cells was performed according to the previous report¹. The FCM analysis using an HLA-A24 tetramer revealed 1% of the CD8⁺ T cells to be EBV-specific cytotoxic T cells, which were markedly increased compared with EBV-specific CD8⁺ T cells in pre-BMT blood (0.1%, day −10), post-rituximab treatment blood (0.2%, day 42), and the donor lymphocyte inoculum (0.1%) (Figure 1). Cytomegalovirus (CMV)-specific CD8⁺ T cells also increased from 0.1% (pre-transplant) to 1.5% after the DLI. CMV antigenemia that occurred on day 31 was no longer detected after day 56. EBV-DNA in blood decreased from 13860 copies/ml on day 45, to 203 copies/ml on day 52, 204 copies/ml on day 95, and became undetectable on day 116. Grade I (skin stage 1) acute GVHD developed 6 days after DLI but was remitted without additional treatments. No signs of chronic GVHD were observed. Although there is persistent B-cell lymphocytopenia (60–120/µl) with hypogammaglobulinemia (IgG levels 220–470 mg/dl), the patient is alive without relapse of either EBV-PTLD or AA as of September, 2015.

Case 2

An 18-year-old man was diagnosed with severe B-cell acute lymphoblastic leukemia (B-ALL) in 2007. Although induction chemotherapy according to the JALSG-ALL202U protocol² induced a CR, his ALL relapsed during the maintenance
chemotherapy in 2008. A reinduction chemotherapy that consisted of high-dose cytarabine (4 g/m²/day × 3 days), pirarubicin (40 mg/m²/day × 5 days), and etoposide (100 mg/m²/day × 5 days) failed to induce a CR. Because no HLA fully-matched donors were found from either relatives or the Japanese marrow donor program (JMDP), he received an allogeneic peripheral-blood stem-cell transplantation (PBSCT) from his 46-year-old mother who was HLA-two loci mismatched (recipient HLA, A 02:07/11:01, B 46:01/52:01, DRB1*01:01/09:01; donor HLA, A 02:07/11:01, B 40:01/46:01, DRB1*09:01/14:05). The conditioning regimen consisted of etoposide (30 mg/m²/day on days −9 and −8), busulphan (3.2 mg/kg/day on days −7 and −6), melphalan (70 mg/m²/day on days −5 and −4), TBI (1 Gy/day on days −4 and −3), and ATG (Thymoglobulin, 2.5 mg/kg/day on days −3 and −2). Prophylaxis for GVHD consisted of tacrolimus (from day −1) and methylprednisolone (40 mg/day, from day 1). The recipient was pre-transplant EBV positive. The neutrophil count surpassed 500/µl on day 10 after PBSCT and the complete hematopoietic donor chimerism was confirmed on day 24. On day 49, atypical lymphocytes (118/µl, 2% of WBC 5900/µl) appeared in the peripheral blood. On day 53 he developed a persistent high fever, systemic lymphadenopathy, and splenomegaly; the WBC count was 2100/µl with 11% atypical lymphocytes and chimerism analysis revealed that they were donor type cells. A bone-marrow study was not performed because of his severe condition. The clonality of CD19+/CD20+ cells of his peripheral blood was confirmed by the predominant Igκ expression using FCM. The EBV-DNA copy number was 600,000/ml of blood. He was diagnosed to have EBV-associated leukemic lymphoma, and was treated with DLI on day 53 (5 × 10⁵ CD3+ cells/kg) and on day 58 (1 × 10⁶ CD3+ cells/kg) in addition to rituximab (375 mg/m² on day 57). Tacrolimus was discontinued from day 55. Despite
these treatments, the number of atypical lymphocytes increased to 4082/µl accounting for 13% of WBC. FCM of peripheral blood on day 59 revealed no CD19+/CD20+ cells and an increase in the CD8+ cell count to 8095/µl. His liver and renal injuries deteriorated and he died of multiple organ failure on day 59. Any symptoms of GVHD were not observed during his clinical course.

3. Other similar and contrasting cases in the literature
Comoli et al reported four cases of CD20-/CD19+ B cells in peripheral blood, accompanied by overt PTLD in 3 patients after haploidentical stem-cell transplantation. The latter cleared PTLD after receiving donor EBV-specific cytotoxic T lymphocytes (CTLs), and persist in remission at a median 30-month follow-up3.

4. Discussion
EBV-PTLD is rare, but is considered to be one of the most serious complications after allogeneic stem-cell transplantation. The fatality rate of EBV-PTLD has been reported to be 50%–92%4-7. Before the rituximab era, unmanipulated DLI was the only effective treatment for EBV-PTLD, although DLI was not potent enough to cure EBV-PTLD and often induced severe GVHD. The effect of DLI is believed to be mediated by T cells specific to EBV specific epitopes such as EBV-BMLF1, EBV-BRLF1, and EBV-EBNA3A8. Although Comoli et al showed that EBV-specific T-cell frequency was restored by EBV-specific CTLs therapy for EBV-PTLD to levels comparable with controls, they evaluated EBV-specific T-cell frequency indirectly using IFN-γ secretion from lymphocytes by ELISPOT assay or flow cytometry3. This is, to our knowledge, the first report to confirm the increase of EBV-specific cytotoxic T cells
using EBV-tetramers after DLI and rituximab treatment directly. Muramatsu et al reported that EBV-tetramer-positive CD8+ cells were detected in the peripheral blood of a patient after radiation and rituximab treatment for EBV-PTLD. In our case, EBV-specific T cells that had been present in the peripheral blood before rituximab treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. This clinical course clearly shows that EBV-specific T cells played a substantial role in eradicating EBV-PTLD.

We experienced four leukemic EBV-PTLD cases (0.5%) among the 797 who received allogeneic stem-cell transplantation (alloSCT) from 1991 to 2013 at our institutes (Table 1). All four patients received ATG-conditioning regimens and it is well known that these regimens induce EBV diseases post-alloSCT due to the level of immunosuppression. Patriarca et al demonstrated that CD4+ T-cell counts <50/µl at day +30 post-alloSCT were significantly associated with an increased risk of high-load EBV-DNAemia (>10000 copies/ml) in alloSCT patients in whom 68% received ATG in their conditioning regimen. Our case 1 patient’s CD4+ T-cell counts were also < 50/µl at day +30 post-alloSCT. Two of the four patients with leukemic EBV-PTLD were treated with DLI or DLI plus rituximab but did not show treatment response; both died due to progressive disease. In the latter case (Case 2) the delayed rituximab administration might have been the cause of the progressive disease. Because monotherapy with rituximab is reported to rescue 63% patients with PTLD, we expected that rituximab therapy would not be able to cure a fulminant EBV-PTLD as seen in our case even in combination with DLI. Cidofovir, a monophosphate nucleotide analogue of cytosine that inhibits viral DNA polymerase, is effective in treating various kinds of viral infections due to adenovirus, BK virus, and EBV. Although the
addition of cidofovir to rituximab-DLI therapy may have helped the patient to overcome such a disastrous condition without obvious adverse effects, there is little evidence to suggest therapeutic efficacy against EBV. It is therefore reasonable to consider EBV-CTL therapy if available to patients who progress under rituximab treatment and DLI.

Acknowledgements

We would like to thank Dr Yoshiyuki Takahashi of Nagoya University for detecting EBV-specific T-cells and Dr Hiroyasu Ogawa of Hyogo College of Medicine for providing us cidofovir. We would also like to express our gratitude to Drs Akiyo Yoshida, Yoshihisa Kumano, Jun Ozaki, and Toshiro Kurokawa of Toyama Prefectural Central Hospital for patients’ clinical information.

Funding

None.

Competing interests

None declared.

Ethical approval

Not required.

Contributors

Hiroyuki Takamatsu and Shinji Nakao managed the patient and wrote the manuscript.
Raita Araki, Ryosei Nishimura, Akihiro Yachie and Kiyotaka Kuzushima performed the detection of EBV-specific cytotoxic T-cells, critically revised and finalized the manuscript. J. Luis Espinoza performed the detection of EBV-DNA, critically revised and finalized the manuscript. Hirokazu Okumura and Takashi Yoshida managed the patient, critically revised and finalized the manuscript.

References


Figure legend

Analysis of EBV specific CD8+ T cells in peripheral blood. Before bone marrow transplant (day -10) (A), donor lymphocytes inoculum (B), post-rituximab treatment (day 42) (C) and post- DLI (day 53) (D). EBV: Epstein-Barr virus, CMV: cytomegalovirus, DLI: donor lymphocyte infusion.
### Table 1. Outcome and treatments of the patients with leukemic EBV-PTLD

<table>
<thead>
<tr>
<th>Case</th>
<th>Year of allo-SCT</th>
<th>Age at allo-SCT</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Conditioning</th>
<th>Stem cell source</th>
<th>Donor</th>
<th>Viral load at onset</th>
<th>Atypical lymphocyte counts at onset (µl)</th>
<th>Treatments of EBV-PTLD</th>
<th>Acute GVHD</th>
<th>Chronic GVHD</th>
<th>Survival post-leukemic EBV-PTLD (days)</th>
<th>Survival post-allo-SCT (days)</th>
<th>Outcome</th>
<th>Cause of death</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2012</td>
<td>34</td>
<td>Female</td>
<td>AA</td>
<td>Flu+CY+ATG+TLI+TBI</td>
<td>BM</td>
<td>MMURD (1 HLA-DR mismatch)</td>
<td>2.4x10^4 copies/ml of blood</td>
<td>150</td>
<td>Rituximab, DLI, cidofovir</td>
<td>Grade I (skin)</td>
<td>None</td>
<td>1264+</td>
<td>1302+</td>
<td>Alive</td>
<td>NA</td>
<td>Our case</td>
</tr>
<tr>
<td>2</td>
<td>2008</td>
<td>18</td>
<td>Male</td>
<td>B-ALL</td>
<td>Mel+Bu+ETP +ATG+TBI</td>
<td>PB</td>
<td>MMURD (1 HLA-B, 1 HLA-DR mismatch)</td>
<td>6x10^5 copies/ml of blood</td>
<td>230</td>
<td>Rituximab, DLI</td>
<td>None</td>
<td>NA</td>
<td>6</td>
<td>59</td>
<td>Dead</td>
<td>Progression of PTLD</td>
<td>Our case</td>
</tr>
<tr>
<td>3</td>
<td>1998</td>
<td>31</td>
<td>Male</td>
<td>AA</td>
<td>CY+ATG+TBI</td>
<td>BM</td>
<td>MMURD (1 HLA-DR mismatch)</td>
<td>1.4x10^5 copies/µl of DNA</td>
<td>15800</td>
<td>DLI</td>
<td>None</td>
<td>NA</td>
<td>11</td>
<td>56</td>
<td>Dead</td>
<td>Progression of PTLD</td>
<td>(11)</td>
</tr>
<tr>
<td>4</td>
<td>1992</td>
<td>28</td>
<td>Female</td>
<td>AML (M2)</td>
<td>CY+Bu→mPSL+ATG</td>
<td>BM</td>
<td>MMURD (1 HLA-DR mismatch)</td>
<td>Not assessed</td>
<td>1800</td>
<td>None</td>
<td>None</td>
<td>NA</td>
<td>8</td>
<td>19</td>
<td>Dead</td>
<td>Development of PTLD, fungal sepsis</td>
<td>(10)</td>
</tr>
</tbody>
</table>
